New drug PEP-010 shows promise in early cancer trial
NCT ID NCT04733027
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new drug called PEP-010 in people with advanced solid tumors that have spread. The study checks if PEP-010 is safe alone or with chemotherapy (paclitaxel or gemcitabine). About 57 adults with metastatic pancreatic, ovarian, or other solid cancers will take part. The goal is to find the best dose and see if the drug shrinks tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
CLCC F.Baclesse Caen
Caen, France
-
Gustave Roussy
Villejuif, France
-
Institut Curie
Paris, 75005, France
-
Institut de Cancerologie de l'Ouest- ICO
Saint-Herblain, 44805, France